A Study Describing the Efficacy and Safety of Belimumab Administered in Adult Participants With Early Systemic Lupus Erythematosus (SLE)
Phase 4
350
about 5 years
18+
46 sites in AL, AZ, CA +12
What this study is about
Researchers are testing belimumab, a medication, in adults with early systemic lupus erythematosus. The trial will last for 3 years to see if belimumab helps manage the condition and how safe it is.
Simplified from trial records by PatientMatch.
What you may be asked to do
- 1.Take Belimumab (GSK1550188)
Participation Burden
What's physically and logistically required of participants.
Requires travel to a study site
How treatment is administered
Everyone gets the investigational treatment.
Extracted study details
Pulled from the trial record to show what is being tested and what the study is measuring.
belimumab
injection (Injection)
Secondary: Part A: Change from Baseline in Functional Assessment of Chronic Illness Therapy (FACIT) -Fatigue at Week 52, Part A: Number of Participants With Adverse Events (AEs), Serious AEs (SAEs), and AEs of Special Interest (AESIs) up to Week 52, Part B: Number of Participants With AEs, SAEs, and AESIs up to Week 104 and Week 156
Immune